Merrimack's Prospects Dim As MM-141 Fails Pancreatic Cancer Phase II Trial
Merrimack Pharmaceuticals has ended development of its experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial.
You may also be interested in...
CEO David Meek Says Ipsen has more than $1bn for M&A use to expand its product line in oncology, neuroscience and rare diseases.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.